Abstract Endotoxic shock is associated with a coagulopathy, organ failure, and death. Tissue factor (TF) expression by monocytes exposed to bacterial endotoxin (lipopolysaccharide [LPS]) may mediate the coagulopathy and contribute to the high mortality of this disease. We examined the role of the LPS-binding protein (LBP)/CD14 receptor pathway in the LPS induction of TF expression in human monocytic THP-1 cells and peripheral blood monocytes. In THP-1 cells, the threshold concentration of LPS required to induce TF activity in serum-free medium was reduced 20-fold by purified LBP, which also enhanced TF mRNA synthesis. Similarly, monocytes cultured in the presence of serum were induced to S eptic shock syndrome, mediated by bacterial endotoxin (lipopolysaccharide [LPS]), is often associated with the development of coagulation disorders including microvascular thrombosis and disseminated intravascular coagulation.
S eptic shock syndrome, mediated by bacterial endotoxin (lipopolysaccharide [LPS])
, is often associated with the development of coagulation disorders including microvascular thrombosis and disseminated intravascular coagulation. 12 The pathophysiology of septic coagulopathy is intimately linked to the expression of the cellular procoagulant tissue factor (TF). In animal models, disseminated intravascular coagulation is induced by administration of either LPS or TF and is prevented by anti-TF antibodies. 3 ' 4 Moreover, inhibition of TF activity in a baboon model of lethal septic shock using a monoclonal antibody attenuates the coagulopathy and protects against lethality, indicating that TF is a mediator of fatal bacteremic shock. 5 Monocytes are the only circulating cell type that can be induced to express TF. 6 These cells may therefore represent the primary source of TF within the vasculature of patients with sepsis. 2 In patients with meningococcal infection increased monocyte TF expression directly correlates with mortality. 7 Experimental studies with leopine, 8 murine, 9 and porcine 10 models of septic shock indicate that monocytes from septic groups consistently express higher levels of TF activity than monocytes from control groups. Moreover, monocytes from rabbits pretreated with endotoxin are thrombogenic and produce pulmonary emboli and death when infused intravenously into untreated rabbits. 11 TF expression is induced on the surface of human peripheral blood monocytes by exposure to LPS in vitro. 1214 One paradigm for LPS activation of monocytes/macrophages involves the binding of LPS to a serum protein termed LPS-binding protein (LBP) and the subsequent engagement of the receptor CD14 by LPS/LBP complexes. LBP is present in human serum at concentrations of 3 to 10 /xg/mL, although levels of this acute-phase protein can rise substantially during a stress response. 15 LBP binds LPS with high affinity and dramatically lowers the threshold dose of LPS required to activate monocytes/macrophages. 1618 LPS/LBP complexes bind to the cell surface of monocytes/macrophages via CD 14, a glycophosphatidylinositol-anchored membrane glycoprotein. 19 Exposure of monocytes/macrophages to LPS stimulates a repertoire of cellular responses, including protein tyrosine phosphorylation, 2021 activation of the nuclear factor KB ( N F -K B ) / Rel family of transcription factors, 22 and expression of genes encoding various cytokines. 2325 Induction of TF expression in monocytic cells exposed to LPS is regulated primarily at the level of gene transcription and requires activation of NF-KB/Rel proteins. 26 " 28 In addition, posttranscriptional control mechanisms contribute to the LPS-induced accumulation of TF mRNA levels in human monocytic THP-1 cells. 27 In this study, we examined the role of the LBP/CD14 pathway in LPS induction of TF expression in monocytic cells. LPS-induced TF activity, TF antigen, and TF mRNA expression were examined in the presence and absence of LBP and in the presence of anti-LBP or anti-CD14 monoclonal antibodies. We showed that the LBP/CD14-dependent pathway played a key role in LPS-induced TF expression in THP-1 cells and freshly isolated human blood monocytes. These studies support the contention that during endotoxemia LPS-induced TF expression is regulated by the LBP/CD14-dependent pathway.
Methods Materials
LPS from Eschtrichia coli O111:B4 was purchased from Calbiochem. LBP isolated from acute-phase rabbit serum 29 was kindly provided by P. Tobias, The Scripps Research Institute, and contained <3 pg/mL LPS contamination as assessed by Limulus amebocyte lysate (LAL) assay (BioWhittaker). 2B5, a murine monoclonal antibody to human LBP, 30 and an immunoglobulin (Ig) Glk isotype control were kindly provided by D. Leturcq and A. Moriarity, R.W. Johnson Pharmaceutical Research Institute. MY4, a murine monoclonal antibody to human CD14, its fiuorescein isothiocyanate (FITC)-labeled conjugate (MY4-FTTC), and isotype controls (murine myeloma IgG2b and IgG2b-FITC) were purchased from Coulter Immunology. TF8-5G9, an anti-human TF antibody, 31 was kindly provided by T.S. Edgington, The Scripps Research Institute. FITC labeling of TF8-5G9 was performed as described. 32 Murine myeloma IgGlk-FITC control was purchased from Zymed.
Cell Culture
The human monocytic leukemia cell line THP-1 was obtained from the American Type Culture Collection. A subline of THP-1 was used for these studies that under the culture conditions described below constitutively expressed approximately 4.7±1.0xl0
4 CD14 molecules per cell as determined by binding of radiolabeled anti-CD14 Fab' fragments. 30 Cells were cultivated at a density of 2 to 5X1O 5 cells/mL in RPMI-1640 medium (BioWhittaker) supplemented with 2 mmol/L glutamine, 10 mmol/L JV-2-hydroxyethylpiperazine-AT'-2-ethanesulfonic acid (HEPES), 50 jimol/L 2-mercaptoethanol, and 7% heat-inactivated fetal calf serum (FCS) (HyClone Laboratories). For selected experiments, cells were cultured in a defined serum-free medium (2 mmol/L glutamine, 10 mmol/L HEPES, and 50 /xmol/L 2-mercaptoethanol; GIBCO). FCS substitutes for purified human or rabbit LBP in promoting the binding of LPS to CD14. 2433 Culture media and FCS were tested by LAL and contained <3 pg/mL LPS contamination.
TF Activity
Cell pellets were solubilized at 37°C for 15 minutes using 15 mmol/L octyl-/3-D-glucopyranoside. TF activity was assayed in cell lysates by using a one-stage clotting assay. 31 Briefly, equal volumes of prewarmed human citrated plasma and 20 mmol/L CaCl 2 were added to test samples at 37°C, and clotting times were determined manually. Clotting times were converted to milliunits of TF activity by comparison with a standard curve established with purified human brain TF. 31 A clotting time of 50 seconds corresponds to 1000 milliunits of TF activity. More than 95% of the procoagulant activity was abolished by incubation with a panel of anti-human TF monoclonal antibodies (TF9-6B4, TF8-9C3, and TF8-11D12), 31 indicating that this activity was due to TF.
Northern Blot Analysis
Total cellular RNA, which was purified by using guanidine thiocyanate-cesium chloride, 34 was analyzed by Northern blotting. 35 A 641-bp human TF cDNA fragment 36 was labeled with [a-^PJdCTP (Amersham Corp) and used to determine TF mRNA levels. To assess variability in sample loading, blots were stripped and rehybridized with a "housekeeping" gene, glucose-6-phosphate dehydrogenase (G6PDH). Autoradiography was performed at -70°C by using Kodak XAR-5 film with intensifying screens. The level of TF mRNA and G6PDH mRNA was quantified by using an LKB Ultroscan XL laser densitometer.
Peripheral Blood Mononuclear Cells and Monocyte Isolation
Blood was drawn from volunteers and heparinized, and plasma was removed after centrifugation at 20Og. Blood cells were diluted 1:1 (vol/vol) in RPMI-1640 medium and overlaid on Ficoll-Hypaque (Pharmacia). After centrifugation at 400g, the peripheral blood mononuclear cells (PBMCs) were removed and washed twice with RPMI-1640. Further purification of monocytes was performed by using Sepracell-MN (Sepratech), which resulted in more than 75% monocytes as determined by fluorescence-activated cell sorting (FACS) using the anti-CD14 antibody MY4-FITC.
FACS Analysis of TF Antigen Expression
After isolation, PBMCs or monocytes were resuspended in polypropylene tubes at a concentration of lxlO 6 cells/mL in RPMI-1640 medium supplemented with 2 mmol/L glutamine with or without 10% FCS or 10% autologous human serum. Pretreatment with the anti-CD14 antibody MY4, the anti-LBP antibody 2B5, or their isotype controls was performed for 15 or 30 minutes at 37°C before addition of LPS. After a 5-hour incubation, cells were washed in phosphate-buffered saline (PBS) and incubated with anti-human TF-FITC, MY4-FITC, or controls for 30 minutes at 4°C. Cells were then fixed in 0.5% paraformaldehyde and analyzed by flow cytometry using an FACScan (Becton Dickinson). Live gating on the monocyte population was accomplished by using near forward-angle and orthogonal light scatter as well as by staining with MY4-FITC antibody.
Statistical Analysis
Data were analyzed with the aid of SIGMASTAT software (Jandel Scientific). Statistical significance was analyzed by Student's / test.
Results

LBP Lowers the Threshold Concentration of LPS That Induces TF Activity in Monocytic THP-1 Cells
Initial experiments used a CD14-positive, human monocytic THP-1 cell line to evaluate the role of the LBP/CD14 pathway in the LPS induction of TF expression. Consistent with our previous studies, 27 exposure of THP-1 cells to LPS for 5 hours in the presence of serum resulted in a dose-dependent increase in TF activity (Fig 1, top ). An LPS dose of 0.1 jtg/mL significantly increased TF activity, although 10 /xg/mL was required for maximal induction. To more directly examine the role of LBP in the LPS induction of TF expression, LPS dose titrations were performed in serum-free medium in the presence and absence of a 10-fold excess (wt/wt) of purified rabbit LBP. In serum-free medium, cells exposed to LPS in the presence of LBP displayed an increase in TF activity at LPS doses of 0.05 and 0.1 /ig/mL (Fig 1, bottom) that was similar to the LPS dose response observed using serum. In contrast, in the absence of added LBP, an LPS dose 20 times higher (1 /ig/mL) was required to induce a significant increase in TF activity (Fig 1, bottom) . Thus, the threshold concentration of LPS required to induce an increase in TF activity in THP-1 cells was reduced 20-fold by purified LBP.
Time Course of LPS-Induced TF Activity in THP-1 Cells
To determine the kinetics of LPS induction of TF expression in the presence of LBP, time-course experiments were performed in serum-free medium. TF activ- ity was rapidly increased by LPS and LBP with a peak at 5 to 6 hours before decreasing to near baseline by 12 hours (Fig 2) . The kinetics of induction of TF activity in serum-free medium in the presence of LBP were essentially identical to our previous studies using serum. 27 No significant induction of TF activity was observed using LPS (0.1 Mg/mL) alone or LBP (1 ^g/mL) alone (Fig 2) . 
LBP Enhances LPS Induction of TF mRNA in THP-1 Cells
Northern blot analysis of TF mRNA levels was performed in seram-free medium to determine if LBP increased the LPS induction of TF mRNA expression. In the absence of LBP, LPS induced a dose-dependent increase in TF mRNA levels at 2 hours (Fig 3) . Nevertheless, induction of TF mRNA levels by a submaximal dose of LPS (0.1 yag/mL) was enhanced by LBP (1 jig/mL) to levels observed using a dose of LPS 100 times greater (10 /xg/mL) alone (Fig 3) . Thus, LPS-induced TF mRNA synthesis in THP-1 cells was enhanced by LBP.
CD14 Mediates LPS/LBP Induction of TF Activity in THP-1 Cells
MY4, a murine monoclonal antibody to human CD14 that blocks binding of LPS/LBP complexes, was used to evaluate the role of CD14 in mediating induction of TF activity. THP-1 cells were pretreated with MY4 for 15 minutes in serum-free medium before addition of LPS and/or LBP. MY4 blocked the increase in TF activity induced by LPS and LBP in a dose-dependent manner (Fig 4) . A significant effect was observed with low doses of MY4 (1 Mg/mL), and a higher dose of MY4 (10 /ig/mL) completely abolished TF induction. LBP (1 jig/mL) alone or MY4 (10 fig/mL ) alone had no effect on levels of TF activity. Therefore, pretreatment of THP-1 cells with an anti-CD14 antibody completely abrogated the enhancing effect of LBP, indicating that induction of TF activity was mediated by the CD14 receptor.
Role of LBP and CD14 in LPS Induction of TF Expression in Human Monocytes
Freshly isolated human peripheral blood monocytes were used as a more physiological model to further cell-MN. This cell population contained between 75% and 85% monocytes and did not express a significant level of TF antigen in the absence of LPS stimulation. Monocytes cultured in the presence of serum exhibited a dose-dependent increase in TF antigen at LPS concentrations between 0.01 and 1 ng/mL (Fig 5) . In contrast, monocytes cultured in serum-free medium did not express TF in response to low doses of LPS (^0.1 ng/mL) but could be induced to express TF by a relatively high dose of LPS (1 ng/mL) (Fig 5) . Therefore, monocytes cultured in the presence of serum were approximately 100 times more sensitive to LPS than monocytes cultured in serum-free medium.
To confirm that the enhancing effect of serum was due to LBP, PBMCs were cultured in autologous serum and pretreated with either the anti-LBP antibody 2B5 or an isotype control antibody for 30 minutes before the addition of LPS. PBMCs exhibited a dose-dependent increase in TF antigen at LPS concentrations between 0.1 and 100 ng/mL (Fig 6) . Pretreatment with an anti-LBP monoclonal antibody resulted in a 90% inhibition of TF expression induced by low concentrations of LPS (0.1 to 1 ng/mL) and a 48% inhibition of TF expression induced by 10 ng/mL LPS (Fig 6 and Table) . The isotype control monoclonal antibody was without effect (data not shown). Thus, LPS-induced TF expression at LPS doses between 0.1 and 1 ng/mL was dependent on the presence of LBP. In contrast, induction of monocyte TF expression by high concentrations of LPS (100 ng/mL) could not be blocked by pretreatment with anti-LBP antibody (Fig 6 and Table) , suggesting the existence of an LBP-independent mechanism for LPS induction of TF expression. In addition, these data indicated that the inhibitory effect of the 2B5 antibody was not due to a toxic effect on the cells. The anti-CD 14 antibody MY4 was used to investigate the role of the CD14 receptor in mediating LPS/LBPinduced TF expression in peripheral blood monocytes. These cells constitutively express high levels of CD14. 37 Pretreatment of PBMCs with MY4 (10 /xg/mL) for 30 minutes before stimulation with LPS resulted in 100%, 84%, and 70% inhibitions of TF expression induced by 0.1, 1, and 10 ng/mL LPS, respectively (Fig 6 and  Table) . MY4 exhibited a similar inhibitory effect on isolated monocytes, reducing TF expression induced by 0.1 ng/mL LPS to baseline values (data not shown). The blocking effect of MY4 was specific in its ability to bind CD 14, as cells pretreated with control antibody (murine IgG2b 10 fig/mL) showed a fluorescence pattern identical to that without antibody (data not shown). Induction of TF expression by high concentrations of LPS (100 ng/mL) was not decreased by the anti-CD14 antibody (Fig 6 and Table) , although we cannot exclude the possibility that these results are due to the displacement of the antibody by LPS. However, increasing the concentration of the anti-CD14 antibody to 20 yug/mL had no effect on the efficacy of blocking (data not shown). Therefore, these results suggest that high concentrations of LPS may induce TF expression via an LBP/ CD14-independent mechanism.
Discussion
This study demonstrated that LPS induction of TF expression in human monocytic cells is mediated by both LBP/CD14-dependent and LBP/CD14-independent pathways, depending on the LPS dose used to stimulate the cells. In freshly isolated human monocytes cultured in autologous serum, low concentrations of LPS (0.1 to 1 ng/mL) induced TF expression via the LBP/CD14 pathway, whereas high concentrations of LPS (100 ng/mL) induced TF expression via an unknown LBP/CD14-independent mechanism. Both pathways appeared to operate at intermediate doses of LPS (10 ng/mL).
Activation of cells via the LBP/CD14 pathway produces rapid changes in intracellular signaling molecules, including tyrosine-phosphorylated proteins.
2021 - 33 LPS induction of TF expression in monocytic cells is dependent on the protein kinase C signaling pathway and requires NF-«B/Rel proteins to increase the rate of TF gene transcription. 28 -38 Further studies will be required to more clearly identify the intracellular mechanisms that lead to TF expression in monocytes. Here, we report that LPS induction of TF mRNA expression, TF surface antigen expression, and TF procoagulant activity were mediated via the LBP/CD14 pathway. In THP-1 cells, LBP enhanced the level of LPS-induced TF activity and TF mRNA. Monocyte TF antigen expression was similarly enhanced in the presence of LBP. THP-1 cells were less responsive to LPS than freshly isolated monocytes. 27 The anti-CD14 antibody MY4 abolished the LPS and LBP induction of TF expression in THP-1 cells and monocytes, indicating that induction was mediated by the CD 14 receptor. Taken together, these results demonstrated that induction of TF expression in monocytic cells exposed to low doses of LPS was mediated by the LBP/CD14 pathway.
Despite the important role of the LBP/CD14 pathway in mediating many of the biological effects of LPS, LBP/CD14-independent pathways exist for LPS binding and cellular activation. 39 - 40 These pathways have been demonstrated in several cell types, including murine pre-B cells that do not express CD14. In the case of LPS induction of TF expression in monocytic cells, LBP/ CD14-independent pathways appear to function at relatively high LPS doses. TF expressed by THP-1 cells exposed to a high dose of LPS (10 /xg/mL) was mediated by an LBP/CD14-independent pathway. Similarly, in peripheral blood monocytes cultured in autologous serum, TF expression induced by 100 ng/mL LPS was independent of LBP and CD14. On the other hand, isolated monocytes cultured in serum-free medium were sensitive to 1 ng/mL LPS, suggesting that LBP/CD14-independent pathways may function at even lower doses of LPS. However, differences between PBMCs and isolated monocytes may reflect the sensitivity of monocytes from different donors or may be due to "priming" of cells during isolation or during culture in serum-free medium. Whether LBP/CD14-independent pathways function under physiological conditions will require further investigation. Gallay et al 41 supporting the contention that the LBP/CD14 pathway mediates many of the deleterious effects of LPS. Endothelial cells are the only vascular cell type other than monocytes that can be induced to express TF in response to LPS. 42 - 43 Importantly, LPS induction of TF mRNA synthesis in human umbilical vein endothelial cells in serum-free medium is dependent on a soluble form of CD14 (sCDM). 44 At the relatively high LPS concentration (100 ng/mL) used in this study the effect of sCD14 appeared to be independent of the presence of LBP. In contrast, the lower concentrations of LPS (<100 ng/mL) that induce interleukin (IL)-6 and IL-8 release by human umbilical vein endothelial cells required both sCD14 and LBP. 45 Nevertheless, these results clearly demonstrate a role for sCD14 in LPS induction of TF gene expression in cells that do not express membrane-bound CD14. This result is particularly relevant in view of the observation that TF is expressed by endothelial cells in vivo in a baboon model of lethal septic shock. 4 * The role of the LBP/CD14 pathway in mediating the clinical sequelae of sepsis remains to be studied in more detail. LPS induction of TF expression on monocytes and endothelial cells via the LBP/CD14 pathway may be teleologically advantageous by limiting rapid spread of bacteria within the circulation. However, much evidence suggests that widespread activation of blood coagulation by TF is a potentially lethal condition. The fact that the LBP/CD14 pathway plays a key role in TF induction in monocytes exposed to low LPS concentrations may be a therapeutic consideration in clinical situations of shock or sepsis, in which LPS levels range between 5 and 100 pg/mL. 47 It is attractive to speculate that by blocking the LBP/CD14 pathway, one might abrogate the deleterious responses of monocytes and endothelial cells, such as widespread coagulation activation, yet preserve normal immune responses and detoxification of LPS. This hypothesis is supported by a study of anti-LBP antibody in mice 41 as well as by current experiments using anti-CD14 monoclonal antibodies in a primate model of endotoxin shock, showing that these antibodies protect against the injurious effects of LPS (R. Ulevitch, et al, unpublished data). The use of anti-LBP or anti-CD 14 antibodies in vivo may prove to be a valuable tool for elucidating the importance of inducible TF activity and in ameliorating the coagulopathy seen in shock and sepsis. 
